ReviewiLIVER2022
Myeloid-derived suppressor cells in cancer.
Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.Oncoimmunology · 2026Article
- Oncolytic Virus VV-GMCSF-Lact and Human GM-CSF Against GL261 Glioma in Immunocompetent Mice.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Resveratrol for Cancer Treatment: Effects on Metabolism and Immune Cells.Biomolecules · 2026Review
- mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.Cancer innovation · 2025Review
- Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system.Molecular cancer · 2025Article
- Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR-T Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Targeting Cancer: Microenvironment and Immunotherapy Innovations.International journal of molecular sciences · 2024Review
- Systemic and local immunosuppression in glioblastoma and its prognostic significance.Frontiers in immunology · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous recent studies have shown that myeloid-derived suppressor cells (MDSCs), a strongly heterogeneous population of immunosuppressive cells, are dysregulated in the presence of many cancers. MDSCs present different phenotypes and play prominent roles in the tumor microenvironment. To date, gene therapies targeting MDSCs are the most innovative and flexible methods to specifically modify the tumor microenvironment. Here, we summarize current studies related to the phenotypes, functions, and mechanisms of MDSCs and explore the therapeutic landscape of chemokines that affect the balance between subpopulations of MDSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.